Spotlighting One-step Multi-Payload Conjugation on Native Unmodified Antibodies to Overcome Tumor Heterogeneity
- Introducing the site-specific conjugation platform process to understand the advantages of having multi payloads on native antibodies
- Demonstrating the efficacy of Dual ADCs in comparison to single-payload ADCs to overcome intra-tumoral heterogeneity
- Validating native antibody-like pharmacokinetics and safety profiles to showcase the benefits of hydrophilic peptide linkers in mitigating aggregation